P,53 INHIBITOR ENHANCES TEMOZOLOMIDE CYTOTOXIC ACTIVITY AGAINST GBM

被引：0
|
作者：
James, C. David [1 ]
Dinca, Eduard
Lu, Kan [1 ]
Prados, Michael [1 ]
Vandenberg, Scott [1 ]
Sarkaria, Jann
Haas-Kogan, Daphne [1 ]
Berger, Mitchel [1 ]
Pieper, Russell [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
NEURO-ONCOLOGY | 2008年 / 10卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：796 / 797
页数：2
相关论文
共 50 条
  • [1] p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts
    Dinca, Eduard B.
    Lu, Kan V.
    Sarkaria, Jann N.
    Pieper, Russell O.
    Prados, Michael D.
    Haas-Kogan, Daphne A.
    VandenBerg, Scott R.
    Berger, Mitchel S.
    James, C. David
    CANCER RESEARCH, 2008, 68 (24) : 10034 - 10039
  • [2] Propentofylline enhances GBM sensitivity to temozolomide via targeting TROY signaling
    Eghlimi, Ryan
    Nascari, David
    Beniwal, Angad
    Alton, Drake
    Grief, Dustin
    Loftus, Joseph
    Haluska, Melanie
    Coleman, David
    Tran, Nhan
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Temozolomide: An oral cytotoxic agent with promising activity against recurrent malignant glioma
    Mason, WP
    ANNALS OF NEUROLOGY, 1999, 46 (03) : 464 - 464
  • [4] Lomitapide enhances cytotoxic effects of temozolomide in chemoresistant glioblastoma
    Ivanova, A.
    Wilson, T. M.
    Ghannad-Zadeh, K.
    Tse, E.
    Wu, M.
    Das, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S113 - S113
  • [5] Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole
    Karve, Aniruddha S.
    Desai, Janki M.
    Dave, Nimita
    Wise-Draper, Trisha M.
    Gudelsky, Gary A.
    Phoenix, Timothy N.
    DasGupta, Biplab
    Sengupta, Soma
    Plas, David R.
    Desai, Pankaj B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (04) : 345 - 356
  • [6] Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole
    Aniruddha S. Karve
    Janki M. Desai
    Nimita Dave
    Trisha M. Wise-Draper
    Gary A. Gudelsky
    Timothy N. Phoenix
    Biplab DasGupta
    Soma Sengupta
    David R. Plas
    Pankaj B. Desai
    Cancer Chemotherapy and Pharmacology, 2022, 90 : 345 - 356
  • [7] THE PI3K INHIBITOR GDC-0941 ENHANCES RADIOSENSITIZATION AND REDUCES CHEMORESISTANCE TO TEMOZOLOMIDE IN GBM CELL LINES
    Shi, Fei
    Guo, Hongchuan
    Zhang, Rong
    Liu, Hongyu
    Wu, Liangliang
    Wu, Qiyan
    Liu, Jialin
    Liu, Tianyi
    Zhang, Qiuhang
    NEUROSCIENCE, 2017, 346 : 298 - 308
  • [8] Decitabine Activity Against TP53-Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis
    Biswas, Sudipta
    Zahran, Zeinab Albadry M.
    Gu, Xiaorong
    Cardone, Lisa
    Jain, Akriti G.
    Fedorov, Kateryna
    Tomlinson, Ben K.
    Goldfinger, Mendel
    Verma, Amit
    Saunthararajah, Yogenthiran
    BLOOD, 2024, 144 : 1382 - 1383
  • [9] Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells
    Thakur, Basant Kumar
    Dittrich, Tino
    Chandra, Prakash
    Becker, Annette
    Kuehnau, Wolfgang
    Klusmann, Jan-Henning
    Reinhardt, Dirk
    Welte, Karl
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (04) : 766 - 774
  • [10] Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide
    Bobustuc, George C.
    Baker, Cheryl H.
    Limaye, Arati
    Jenkins, Wayne D.
    Pearl, Gary
    Avgeropoulos, Nicholas G.
    Konduri, Santhi D.
    NEURO-ONCOLOGY, 2010, 12 (09) : 917 - 927
12345